Answers are grounded in this paper and cite their sources.
Rheumatoid arthritis (RA) is an inflammatory disease that causes persistent systemic inflammation and progressive joint destruction, which can result in lifelong disability. RA pathogenesis involves a complicated network of cytokines that stimulate synovial cell growth and induce cartilage and bone degradation. Variations in cytokine expression profiles play a key role in the persistence of inflammation and joint damage in RA. The complex interactions have been emerged as an important factor regulating RA susceptibility, disease severity, and treatment effects. Production of these cytokines, at large, is affected by variations in cytokine genes. Targeted medicines that attempt to block specific cytokines or regulate intracellular signaling pathways have drastically altered RA treatment. Biologic disease-modifying antirheumatic drugs that target cytokines and small molecule inhibitors that disrupt intracellular signaling have shown efficacy in controlling RA symptoms and slowing disease progression. The present review collectively summarizes the association of cytokine gene polymorphisms in susceptibility toward RA in different populations. In addition, the various emerging biological therapies in RA involving cytokines as targets have been discussed. More research into the complex links between cytokine dysregulation, genetic variability and treatment responses will pave the way for more precise and successful RA management options.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: